The pretreatment of lymphoma cells with decitabine, a DNMTi, was shown to lead to the increased expression of the surface antigen CD19 on lymphoma cells, making them more susceptible to CD19 CAR T cells; this was observed in two lymphoma patients who were treated with decitabine before CAR T-cell therapy and achieved complete remission [127]. Here, CD19 is linked to lymphoma.